Relationship of serum haloperidol levels to clinical response in schizophrenic patients
Abstract
The authors treated 16 outpatients and 1 inpatient who had diagnoses of schizophrenia in exacerbation with haloperidol as the sole neuroleptic agent and obtained ratings of psychopathology and serum levels of haloperidol. Improvement in schizophrenic symptoms measured by the Brief Psychiatric Rating Scale was significantly greater in patients who had mean haloperidol serum concentrations in the range of 8-18 ng/ml than in patients whose mean haloperidol serum concentration fell outside this range.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
